Evidence tracker Chronic pain Knee

Genicular nerve radiofrequency ablation

For chronic knee pain from osteoarthritis, including after total knee arthroplasty. Conventional, cooled and pulsed techniques compared against sham, intra-articular injections and usual care.

Indexed papers
14
matching, retractions excluded
Randomized trials
1
plus 0 meta-analyses
With AI summary
14
others show original abstract
Registered, not results
18
ongoing trials
Clinical assessment not completed. No bottom line, certainty grade, or curated effect sizes have been written for this topic. Below is a source-linked inventory of matching papers (up to 200 from our cache), not a systematic review. Read the original studies before drawing conclusions.

Published studies

Open in feed

Recent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.

Showing 4 of 14 · Review

Recent evidence · past year

  1. Review Reg Anesth Pain MedPublished 5 Oct 2026 Ferreira-Silva N et al.
    Navigating current controversies in radiofrequency ablation of the genicular nerves for chronic knee pain in osteoarthritis: a daring discourse.
    AI summary of the abstract, unverified
    • This is a narrative discourse rather than a trial, reviewing debates on radiofrequency ablation of the genicular nerves for chronic knee osteoarthritis pain.
    • It addresses six controversies: prognostic blocks, final cannula placement, which nerves to target, ultrasound versus fluoroscopy, pulsed radiofrequency, and use after knee arthroplasty.
    • The abstract notes earlier studies reporting pain relief lasting up to 12 months, while recent randomized trials have questioned RFA efficacy.
    • The authors attribute conflicting results partly to heterogeneity in patient selection and technical protocols, and aim to guide clinicians and prompt further research.
    Original abstract (PubMed)

    Chronic knee joint pain affects millions worldwide, with radiofrequency ablation (RFA) of genicular nerves emerging as a potential treatment in the last 15 years. Despite its growing popularity, with studies demonstrating its efficacy in pain reduction for up to 12 months, recent randomized controlled trials have questioned the efficacy of RFA. Discrepancies in study results may partially be explained by the heterogeneity of patient selection and technical protocols.This daring discourse aims to explore and critically analyze the ongoing debates surrounding RFA of the genicular nerves, addressing key controversies, namely: (1) Is there a role for performing prognostic blocks prior to RFA?; (2) What are the optimal target sites for final cannulae placement for the classical targets?; (3) Which and how many nerves should be targeted in RFA procedures?; (4) What are the comparative benefits of using ultrasound versus fluoroscopy guidance, and whether a combined technique may be advantageous?; (5) Is there a potential role for pulsed radiofrequency of the genicular nerves?; (6) Should genicular nerve RFA be performed after total knee arthroplasty?Through this in-depth discussion, we aim to guide pain medicine clinicians in informed decision-making and encourage further research in this field.

  2. Review CureusPublished 23 Sep 2026 Zuccarini F et al.
    One Size Does Not Fit All: A Systematic Review of Preoperative Genicular Nerve Radiofrequency Ablation in Total Knee Arthroplasty.
    AI summary of the abstract, unverified
    • This systematic review pooled prospective randomized trials and observational studies of preoperative genicular nerve radiofrequency ablation before total knee arthroplasty.
    • The comparison was ablation against control procedures, assessing function, pain, opioid use, length of stay, and complications.
    • Trials showed no meaningful improvement in medium- to long-term function, acute pain, or length of stay, and no clear rise in complications was found.
    • Retrospective data hinted at fewer long-term opioid refills, but no study stratified outcomes by baseline risk, so high-risk patients remain untested.
    Original abstract (PubMed)

    Persistent postsurgical pain and poor functional recovery remain significant challenges following total knee arthroplasty, with patients presenting with severe preoperative pain, central sensitization, or psychological comorbidities at elevated risk. Preoperative genicular nerve radiofrequency ablation aims to preemptively block nociceptive signaling via thermal neuro-destruction or sensory neuromodulation, but its clinical utility remains debated. This systematic review evaluates whether ablation improves functional outcomes, pain trajectories, and opioid consumption after primary joint replacement, focusing on vulnerable populations. Following established reporting guidelines, major biomedical databases were comprehensively searched to identify prospective randomized trials and observational studies evaluating functional scores, pain intensity, opioid consumption, length of stay, and complication rates. No clear increase in reported complications was identified in the available studies, although the evidence base is insufficient to exclude uncommon adverse events. Trial evidence showed no statistically or clinically meaningful improvements in medium- to long-term functional scores, acute postoperative pain, or length of stay compared to control procedures. While retrospective database data suggested a potential reduction in long-term opioid refills, none of the available literature stratified outcomes based on baseline patient risk profiles. Preoperative genicular nerve radiofrequency ablation is safe, but current evidence does not support its routine, unselected application in general surgical populations. Its true clinical value remains untested in high-risk individuals predisposed to chronic postsurgical pain, highlighting a clear need for targeted, risk-stratified trials.

  3. Review Skeletal RadiolPublished 15 Sep 2026 Gonzalez FM et al.
    Local anesthetic selection for spine and large joint radiofrequency ablation: a practical review for the musculoskeletal radiologist.
    AI summary of the abstract, unverified
    • This narrative practical review synthesizes indirect pharmacological and adjacent procedural evidence, with no dedicated comparative trial of local anesthetics within RFA.
    • It suggests lidocaine 1% as a default for skin and track anesthesia, and avoiding lidocaine 2% near the target nerve where stimulation testing is done, based on mechanistic reasoning.
    • Across five randomized trials outside interventional pain settings, premixing lidocaine and bupivacaine showed no onset advantage over bupivacaine alone and sometimes shortened duration.
    • The authors conclude these considerations are provisional and call for prospective studies, and they provide an allergy substitution pathway centered on formal allergist evaluation.
    Original abstract (PubMed)

    Local anesthetic (LA) selection for radiofrequency ablation (RFA) of spinal medial branch nerves, sacroiliac joint lateral branches, and large peripheral joint articular branches has not been addressed by any dedicated document. The concentration, class, and sequencing of agents used during needle placement, stimulation testing, and pre-lesioning injection have plausible implications for procedural accuracy and post-procedural analgesia. This review synthesizes pharmacological data and adjacent procedural literature into practice considerations for the musculoskeletal radiologist. No randomized or prospective comparative trial has evaluated LA agents, concentrations, or sequencing within an RFA procedure; every statement therefore rests on indirect evidence, mechanistic reasoning, or the authors' practice, and each is labeled accordingly. Lidocaine 1% is a reasonable default for skin, subcutaneous, and deep track anesthesia. Where sensory and/or motor stimulation testing is performed, there is a mechanistic argument for avoiding lidocaine 2% close to the target nerve, since selectivity between fiber classes falls as concentration rises; that argument derives from epidural quantitative sensory testing and rodent electrophysiology, has not been tested in RFA, and no study has shown that lidocaine 2% impairs stimulation testing or procedural outcome. Bupivacaine 0.25% or ropivacaine 0.2% is a reasonable choice for perineural injection before lesioning. Premixing lidocaine and bupivacaine has no demonstrated advantage: across five randomized trials, all outside interventional pain settings and heterogeneous in design, mixtures did not accelerate onset relative to bupivacaine alone and in several curtailed its duration; two also found same-site sequential injection no better than premixing. Ropivacaine is a reasonable preference in cardiac conduction disease or multi-level procedures. A structured allergy substitution pathway is provided with formal allergist evaluation as the central step. These considerations are offered to inform practice and to prompt the prospective studies the field lacks.

  4. Review Ann R Coll Surg EnglPublished 19 Aug 2026 Onobun D et al.
    Comparative outcomes of genicular nerve block and radiofrequency ablation in knee osteoarthritis.
    AI summary of the abstract, unverified
    • This PRISMA systematic review pooled 19 studies, including sham-controlled trials, active-comparator trials and cohorts, of genicular nerve block and radiofrequency ablation for knee osteoarthritis.
    • Pooled random-effects meta-analysis was used where data were homogeneous, and structured narrative synthesis otherwise.
    • RFA was associated with larger and more durable pain relief than GNB, often lasting 6-12 months, though most of the comparison evidence is indirect.
    • Both approaches reduced pain with no serious procedure-related adverse events reported, and the authors call for head-to-head trials with standardised protocols and longer follow-up.
    Original abstract (PubMed)

    INTRODUCTION: Genicular nerve block (GNB) and radiofrequency ablation (RFA) are increasingly utilised for pain management in knee osteoarthritis, yet their comparative effectiveness, durability and clinical role remain uncertain. This systematic review aimed to compare outcomes of GNB and RFA in patients with knee osteoarthritis. METHODS: A systematic review was conducted in accordance with PRISMA guidance. MEDLINE, Embase, CENTRAL, CINAHL and Web of Science were searched for randomised controlled trials and comparative observational studies evaluating GNB and/or RFA for knee osteoarthritis. Outcomes included pain, function, durability of effect, safety and reported progression to total knee replacement (TKR). Random-effects meta-analysis was performed where data were sufficiently homogeneous; otherwise, structured narrative synthesis was undertaken. FINDINGS: Nineteen studies were included, comprising sham-controlled trials, active-comparator trials and prospective or retrospective cohorts. Both GNB and RFA were associated with reductions in pain compared with comparators. Across studies, RFA demonstrated larger and more durable pain relief than GNB, with benefits commonly sustained for 6-12 months and, in some cohorts, beyond 1 year. Functional improvements were variable but were most consistently observed following RFA using broader genicular nerve targeting strategies. No serious procedure-related adverse events were reported, and minor complications were infrequent and self-limiting. Reported conversion to TKR during study follow-up was rare, though follow-up duration and study design limited causal inference. CONCLUSIONS: Genicular nerve interventions provide clinically meaningful pain relief with favourable safety profiles in knee osteoarthritis. Across the available studies, RFA was associated with larger and more durable improvements in pain than GNB, although most evidence derives from indirect comparisons rather than direct head-to-head trials. Further high-quality studies with standardised protocols and longer follow-up are required to clarify long-term outcomes and surgical implications.

Earlier evidence / dates not confirmed

Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.

  1. No matching papers in this section with the selected filters.

Ongoing registrations

From ClinicalTrials.gov

Registrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.

Recruiting, est. 2026-08-31
Active not recruiting, est. 2026-12
Not yet recruiting, est. 2026-12-01
Not yet recruiting, est. 2027-03-30
Not yet recruiting, est. 2027-04-30
Recruiting, est. 2027-06-01
Radiofrequency in Knee Osteoarthritis
NCT07700784, target n=50
Not yet recruiting, est. 2027-08
Recruiting, est. 2027-08-20
Recruiting, est. 2028-07-14
Not yet recruiting, est. 2028-08-20
Not yet recruiting, est. 2028-10